Clinical Trials Arena on MSN

Zenas’ bifunctional mAb scores at Phase II in relapsing MS

During the Phase II MoonStone study (NCT06564311), the bifunctional monoclonal antibody (mAb) met its primary endpoint, ...
TipRanks on MSN

Zenas BioPharma says obexelimab met primary endpoint in Phase 2 MoonStone trial

Zenas BioPharma (ZBIO) announced results from the Phase 2 MoonStone trial of obexelimab in Relapsing Multiple Sclerosis. Obexelimab met the ...
Investing.com South Africa

Zenas BioPharma stock soars after positive MS drug trial results

Investing.com -- Zenas BioPharma (NASDAQ:ZBIO) stock surged 80% on Monday after the company announced positive results from its Phase 2 MoonStone trial of obexelimab in Relapsing Multiple Sclerosis ...

Zenas BioPharma Announces Positive Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis

Obexelimab met primary endpoint with a 95% relative reduction in new gadolinium (Gd)-enhancing T1 lesions compared with placebo, p=0.0009 - WALTHAM, Mass., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Zenas ...